anxiety in the post-blockbuster era
Time：
2026-03-20 08:23
Author：
xieyijun
“Abandoned by Giants” Bets Big on ADC
Time：
2026-03-19 08:13
Author：
xieyijun
Pfizer’s Ignite Goes Up in Smoke
Pfizer Discontinues a Business Unit
Time：
2026-03-18 08:18
Author：
xieyijun
2026 Biotech: Exits and Entries
Layoffs and Restructuring, Divergence and Hope
Time：
2026-03-17 08:17
Author：
xieyijun
In vivo CAR-T, "saturated innovation" after one year
The blind box is about to be opened
Time：
2026-03-14 19:10
Author：
xieyijun
When Bank Capital Floods the Innovative Drug Sector
How to make good use of bank capital?
Time：
2026-03-13 18:31
Author：
xieyijun
War and Peace in the mRNA Patent Wars
When Will the Wave of Lawsuits End?
Time：
2026-03-13 08:22
Author：
xieyijun
BioNTech’s Turbulent Transition: Old Guard Out, New Era In
Assets Supporting the Future Lie in Its "China Circle"
Time：
2026-03-12 09:21
Author：
xieyijun
Recommended content
mRNA tumor vaccine "seller", entering a golden age
When a Biotech company that has been acquired achieves rare growth
AI、 Cold bench and puzzle, when will 'one person, one seedling' come to an end?
This road is long, but the threshold has already been crossed.
The "economic accounts" of immunology business development are being rewritten
After rejecting a $30 billion acquisition offer, a biotech company has emerged as a giant
determination for independence
联系我们
同写意
写意宣发
同写意Biotech
同写意微服务